Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Embase Enhances Adverse Event Monitoring

Published: Friday, May 30, 2014
Last Updated: Friday, May 30, 2014
Bookmark and Share
With Embase and PharmaPendium, researchers can monitor pre-clinical, clinical and post-market information from a single search - improving pharmacovigilance and risk monitoring.

Elsevier has announced an enhanced risk monitoring and pharmacovigilance solution with Embase, its biomedical database, now seamlessly connecting to PharmaPendium, a source of extensive regulatory data. Embase is the world's most comprehensive international biomedical database that enables tracking and retrieval of valuable drug- and disease-specific information; PharmaPendium aggregates the most extensive drug-related regulatory information that supports critical drug development decisions. Both are part of the Elsevier Life Science Solutions Portfolio.

A single drug search in Embase will provide an overview of key information pertaining to the drug of interest, including a snapshot of pre-clinical, clinical and post-marketing reported adverse events. Embase customers with a subscription to PharmaPendium can also link directly into a wealth of regulatory data including FDA and EMA approval documents from the results of their original search query.

Pharmacovigilance workflows are improved with risk monitoring based upon more comprehensive data. Together, the two products support more efficient drug development research and more effective management of post-launch risks.

“Whether working on the development of a new drug or monitoring the safety of an existing drug or device, it’s crucial that pharmaceutical companies have access to actionable data that improves risk monitoring and saves valuable time,” said Daan de Jong, Director Product Development for Elseiver.“We’ve linked Embase and PharmaPendium to allow scientists to navigate a vast amount of drug safety data and to easily obtain relevant drug information in a single search. Offering complementary solutions is a significant milestone that augments the value of the Elsevier Life Science Solutions portfolio which enables scientists from diverse disciplines to collaborate, accelerate and achieve better R&D outcomes.”

Embase customers were automatically upgraded to a new version on April 30, 2014. In addition to the seamless connection to PharmaPendium, the user experience was improved other additional new Embase enhancements including:

• Text-filter export - allows users to export filter data up to a 2,000-variable limit to easily produce and share crucial lists; for example, a complete list of diseases found in combination with a particular drug search. Users can also explore potential relationships - including those between specific drugs and devices - based on the literature.
• Streamlined search forms - users can review all search options without scrolling down the page and the newly designed auto-complete function offers suggestions for search terms covering drug and disease queries.
• Faster search - speeds have improved even for users who access Embase from behind strict company firewalls and proxies.

Embase and PharmaPendium are part of Elsevier's Life Science Solutions, a portfolio of domain-specific, decision support tools which span the discovery and development workflow and work together to support key research outcomes. The portfolio includes Pathway Studio, ScienceDirect, Scopus, TargetInsights, Reaxys, Reaxys Medicinal Chemistry and QUOSA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Elsevier Acquires Aureus Sciences
Elsevier purchases content assets including databases and information tools for pharmaceutical and biotech companies.
Thursday, January 24, 2013
Scientific News
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Personalised Medicine: Dose by Design
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs, as Congenica's Nick Lench discussed on a recent BBC Radio 4 programme.
Expanding Knowledge of Viral Diversity
Environmental datasets help researchers double the number of microbial phyla known to be infected by viruses.
Computers Better Predict Lung Cancer Type, Severity
Study shows automating the analysis of cancer tissue samples increases the accuracy of tumor classification and patient prognoses.
Using Big Data to Discover Potential Cancer Biomarkers
University of Hawai'i Cancer Center researchers used "Big Data" to discover potential cancer biomarkers, a panel of six long intergenic non-coding RNAs (lincRNAs), for the diagnosis of all types of cancers including lung, breast, prostate, liver and ovarian cancers.
Protecting Privacy in Genomic Databases
System helps ensure databases used in medical research will not leak patients’ personal information.
Algorithm To Find Precise Cancer Treatments For Patients Developed
The JAMMIT algorithm could help predict which patients will benefit most from chemotherapy.
Depression Genetics Insight from Crowd-Sourced Data
Genome sites liked to depression have been discovered from data shared by people who had purchased their genetic profiles online.
Detecting Hazardous Chemicals in Complex Mixtures
Researchers are pioneering a new chemical substance analyis software technique that could increase illicit substance detection.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!